CP-55,244
A tricyclic non-classical cannabinoid from Pfizer, a research tool of very high affinity at the CB1 receptor.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₆H₄₂O₃
CAS 79732-51-7
- Family
- Synthetic CB receptor agonistResearch ligand or medicine
- Molar mass
- 402.60 g/mol
Updated on
In plain terms
CP-55,244 is a laboratory cannabinoid, made rigid, used as a research tool at the CB1 receptor. In published assays it proves very potent. It is not meant to be consumed.
Receptors and activity
Target network
- Activates
The lower the cited value, the closer the target sits to CP-55,244: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of CP-55,244.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1AgonistEC50 = 0.5 nM · rat89 out of 100
Griffin et al. 1998, J Pharmacol Exp Ther (new tab) · [35S]GTPγS binding, rat cerebellar membranes; Ki = 1.4 ± 0.3 nM cited by Lagu 1995
- CB2Agonistno measured value cited
Assessed at rat, mouse and recombinant human receptors (Govaerts 2004); value not found in the abstract
Pharmacology
CP-55,244 is a non-classical cannabinoid of the ACD-tricyclic type: its phenol with a 1,1-dimethylheptyl chain is carried by a decalin that fixes the position of the hydroxypropyl group of CP-55,940 (Melvin et al. 1995). In rat cerebellar membranes, it stimulates [35S]GTPγS binding with an EC50 of 0.47 nM, values that the authors place at the top end of the range observed (Griffin et al. 1998). In mice, (-)-CP-55,244 and (-)-CP-55,940, which lack the pyran ring, are 5 to 775 times more potent than Δ9-THC on several behavioural measures (Little et al. 1988), and (-)-CP-55,244 is about 1000 times more potent than Δ9-THC at enhancing [3H]flunitrazepam binding and in an analgesic activity measured in animals (Koe et al. 1985). Richardson et al. (1990) took it as the basis for affinity ligands of the cannabinoid receptor. No human data were found: the compound is a pharmacological tool.
Key sources.
- Griffin G, Atkinson PJ, Showalter VM, Martin BR, Abood ME. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther. 1998;285(2):553-560 (new tab)PMID 9580597
- Melvin LS, Milne GM, Johnson MR, Wilken GH, Howlett AC. Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity. Drug Des Discov. 1995;13(2):155-166 (new tab)PMID 8872458
- Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther. 1988;247(3):1046-1051 (new tab)PMID 2849657
- Koe BK, Milne GM, Weissman A, Johnson MR, Melvin LS. Enhancement of brain [3H]flunitrazepam binding and analgesic activity of synthetic cannabimimetics. Eur J Pharmacol. 1985;109(2):201-212 (new tab)PMID 2986995
- Lagu SG, Varona A, Chambers JD, Reggio PH. Construction of a steric map of the binding pocket for cannabinoids at the cannabinoid receptor. Drug Des Discov. 1995;12(3):179-192 (new tab)PMID 7662829
- Council Framework Decision 2004/757/JHA, consolidated version of 12.01.2026 (annex: substances subject to Union control) (new tab)
History
- Source
- A wholly synthetic compound, with no natural occurrence, used as a pharmacological research tool at the cannabinoid receptor (see Griffin et al. 1998; Govaerts et al. 2004). No report of circulation outside the laboratory was found in the sources consulted.
Origin
Laboratory synthesis
No biological pathway: CP-55,244 is entirely synthetic and belongs to the class of the non-classical cannabinoids, without the pyran ring of THC.
Legal framework
- European Union
It does not appear in the annex to Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which names only five synthetic cannabinoid agonists: MDMB-CHMICA, ADB-CHMINACA, CUMYL-4CN-BINACA, MDMB-4en-PINACA and 4F-MDMB-BICA. Nor does it appear in annex III of the consolidated ANSM list (tables I and II of the 1971 Convention on Psychotropic Substances).
- France
Not named in the consolidated ANSM list (updated 16 February 2026). Literal reading of a generic clause: annex IV covers the cyclohexylphenols, derivatives of 2-(3-hydroxycyclohexyl)phenol bearing in position 5 of the phenol ring an alkyl-type substituent and whose cyclohexyl ring is substituted or not, and names CP 55,940 and the CP 47,497 compounds under this clause. CP-55,244 is a phenol with a 1,1-dimethylheptyl chain (alkyl, in position 5) carried by a decalin whose phenol-bearing ring is a hydroxycyclohexyl in a 1,3 relative position: it can be read as a 2-(3-hydroxycyclohexyl)phenol whose cyclohexyl is substituted by the fusion of a second ring. This reading has been the subject of no known decision and remains more fragile than a listing by name.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Synthetic CB receptor agonist › Research ligand or medicine
- Class
non-classical
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Griffin G, Atkinson PJ, Showalter VM, Martin BR, Abood ME. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther. 1998;285(2):553-560 (new tab)PMID 9580597
- Melvin LS, Milne GM, Johnson MR, Wilken GH, Howlett AC. Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity. Drug Des Discov. 1995;13(2):155-166 (new tab)PMID 8872458
- Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther. 1988;247(3):1046-1051 (new tab)PMID 2849657
- Koe BK, Milne GM, Weissman A, Johnson MR, Melvin LS. Enhancement of brain [3H]flunitrazepam binding and analgesic activity of synthetic cannabimimetics. Eur J Pharmacol. 1985;109(2):201-212 (new tab)PMID 2986995
- Lagu SG, Varona A, Chambers JD, Reggio PH. Construction of a steric map of the binding pocket for cannabinoids at the cannabinoid receptor. Drug Des Discov. 1995;12(3):179-192 (new tab)PMID 7662829
- Council Framework Decision 2004/757/JHA, consolidated version of 12.01.2026 (annex: substances subject to Union control) (new tab)
Identifiers
Names
- IUPAC name
- (2R,4R,4aR,6S,8aS)-6-(hydroxymethyl)-4-[2-hydroxy-4-(2-methyloctan-2-yl)phenyl]-1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol
- Other names
- CP 55,244 · CP-55244 · CP55244
Identifiers
- Formula
- C₂₆H₄₂O₃
- CAS
- 79732-51-7
- PubChem CID
- 9844074(new tab)
- InChIKey
- ZAELPWSCABXXAB-NWXGMGMZSA-N
- SMILES
- CCCCCCC(C)
(C) C1= CC(= C(C= C1) [C@@H] 2C[C@@H] (C[C@H] 3[C@H] 2C[C@H] (CC3) CO) O) O
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.